calcium channel, voltage-dependent, L type, alpha 1D subunit |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl-D-aspartate 3B |
GREPAFLOXACIN |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
GREPAFLOXACIN |
Adrenergic alpha2B |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2D |
GREPAFLOXACIN |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, NMDA2C |
GREPAFLOXACIN |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2B |
GREPAFLOXACIN |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
calcitonin receptor |
PRILOCAINE |
Calcitonin |
-17% |
NoneNone |
NoneNone |
View
|
acetylcholinesterase (YT blood group) |
GLYPHOSATE |
Acetylcholinesterase |
-17% |
NoneNone |
NoneNone |
View
|
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
GLYPHOSATE |
Acetylcholinesterase |
-17% |
NoneNone |
NoneNone |
View
|
acetylcholinesterase |
GLYPHOSATE |
Acetylcholinesterase |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
GREPAFLOXACIN |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
GREPAFLOXACIN |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 1B |
GREPAFLOXACIN |
Serotonin 5-HT1B |
-17% |
NoneNone |
NoneNone |
View
|
A3 adenosine receptor |
PHENELZINE |
Adenosine A3 |
-17% |
NoneNone |
NoneNone |
View
|
protein kinase C, alpha |
LOMUSTINE |
Protein Serine/Threonine Kinase PKCalpha |
-17% |
NoneNone |
NoneNone |
View
|
protein kinase C, alpha |
LOMUSTINE |
Protein Serine/Threonine Kinase PKCalpha |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, gamma 1 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, pi |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
AT hook, DNA binding motif, containing 1 (DBSS) |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, theta |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, gamma 2 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, alpha 2 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, alpha 1 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, delta |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 |
PIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
angiotensin 1 converting enzyme 1 |
PIROXICAM |
Protease, Angiotensin Converting Enzyme |
-17% |
NoneNone |
NoneNone |
View
|
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
PIROXICAM |
Protease, Angiotensin Converting Enzyme |
-17% |
NoneNone |
NoneNone |
View
|
cannabinoid receptor 1 (brain) |
PHENELZINE |
Cannabinoid CB1 |
-17% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 4 |
LISINOPRIL |
Serotonin 5-HT4 |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 1b |
10,11-DIHYDRO-CARBAMAZEPINE |
Adrenergic alpha1B |
-17% |
NoneNone |
NoneNone |
View
|
cannabinoid receptor 1 (brain) |
IVERMECTIN |
Cannabinoid CB1 |
-17% |
NoneNone |
NoneNone |
View
|
adenosine A2a receptor |
O-ANISIDINE |
Adenosine A2A |
-17% |
NoneNone |
NoneNone |
View
|
cysteinyl leukotriene receptor 1 |
DIATRIZOIC ACID |
Leukotriene D4 |
-17% |
NoneNone |
NoneNone |
View
|
cysteinyl leukotriene receptor 1 |
DIATRIZOIC ACID |
Leukotriene D4 |
-17% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 3 |
DIATRIZOIC ACID |
Protein Serine/Threonine Kinase, ERK1 |
-17% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 3 |
DIATRIZOIC ACID |
Protein Serine/Threonine Kinase, ERK1 |
-17% |
NoneNone |
NoneNone |
View
|
epidermal growth factor receptor |
VALSARTAN |
Protein Tyrosine Kinase, EGF Receptor |
-17% |
NoneNone |
NoneNone |
View
|
monoamine oxidase A |
VALSARTAN |
Monoamine Oxidase MAOA |
-17% |
NoneNone |
NoneNone |
View
|
monoamine oxidase A |
VALSARTAN |
Monoamine Oxidase MAOA |
-17% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 3 |
PENICILLAMINE |
Protein Serine/Threonine Kinase, ERK1 |
-17% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 3 |
PENICILLAMINE |
Protein Serine/Threonine Kinase, ERK1 |
-17% |
NoneNone |
NoneNone |
View
|
synaptic vesicle glycoprotein 2b |
DIHYDROERGOCRISTINE MESYLATE |
beta-Lactamase |
-17% |
NoneNone |
NoneNone |
View
|
chemokine (C-C motif) receptor 2 |
NALTREXONE |
Chemokine CCR2B |
-17% |
NoneNone |
NoneNone |
View
|
epidermal growth factor receptor |
AZASETRON |
Protein Tyrosine Kinase, EGF Receptor |
-17% |
NoneNone |
NoneNone |
View
|
androgen receptor |
CYROMAZINE |
Testosterone |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
NALTREXONE |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
NALTREXONE |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
interleukin 8 receptor, alpha |
TERBINAFINE |
Chemokine CXCR1(IL-8A) |
-17% |
NoneNone |
NoneNone |
View
|
phosphodiesterase 3B |
CYROMAZINE |
Phosphodiesterase PDE3 |
-17% |
NoneNone |
NoneNone |
View
|
phosphodiesterase 3A |
CYROMAZINE |
Phosphodiesterase PDE3 |
-17% |
NoneNone |
NoneNone |
View
|
neuropeptide Y receptor Y1 |
SECOBARBITAL |
Neuropeptide Y1 |
-17% |
NoneNone |
NoneNone |
View
|
calcitonin receptor |
ROXITHROMYCIN |
Calcitonin |
-17% |
NoneNone |
NoneNone |
View
|
chemokine (C-C motif) receptor 5 |
SULFINPYRAZONE |
Chemokine CCR5 |
-17% |
NoneNone |
NoneNone |
View
|
nuclear receptor subfamily 3, group C, member 1 |
CYROMAZINE |
Glucocorticoid |
-17% |
NoneNone |
NoneNone |
View
|
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
TORSEMIDE |
Dopamine Transporter |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2D |
TORSEMIDE |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
CHLORDIAZEPOXIDE |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
monoamine oxidase A |
AZITHROMYCIN |
Monoamine Oxidase MAOA |
-17% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 2C |
PHENYLBUTAZONE |
Serotonin 5-HT2C |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
PHENYTOIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 8 |
AZITHROMYCIN |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 5 (DBSS) |
AZITHROMYCIN |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 1b |
AZITHROMYCIN |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 1a |
AZITHROMYCIN |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 4 |
AZITHROMYCIN |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
AZITHROMYCIN |
Tumor Necrosis Factor (TNF), Non-Selective |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA1 (alpha 1) |
AMPRENAVIR |
Glutamate, AMPA |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA2 |
AMPRENAVIR |
Glutamate, AMPA |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA3 (alpha 3) |
AMPRENAVIR |
Glutamate, AMPA |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor subunit 4c |
AMPRENAVIR |
Glutamate, AMPA |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 2a |
BUSULFAN |
Imidazoline I2, Central |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
BUSULFAN |
Imidazoline I2, Central |
-17% |
NoneNone |
NoneNone |
View
|
cannabinoid receptor 1 (brain) |
CARMOFUR |
Cannabinoid CB1 |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, gamma 1 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, pi |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
AT hook, DNA binding motif, containing 1 (DBSS) |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, theta |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, gamma 2 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, alpha 2 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, alpha 1 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid A receptor, delta |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 |
AMPIROXICAM |
GABAA, Agonist Site |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
NIFURSOL |
Adrenergic alpha2B |
-17% |
NoneNone |
NoneNone |
View
|
glycine receptor, alpha 3 |
PROCARBAZINE |
Glycine, Strychnine-Sensitive |
-17% |
NoneNone |
NoneNone |
View
|
glycine receptor, alpha 1 subunit |
PROCARBAZINE |
Glycine, Strychnine-Sensitive |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
CORTISONE ACETATE |
Calcium Channel Type L, Phenylalkylamine |
-17% |
NoneNone |
NoneNone |
View
|
insulin receptor |
BENZOTHIAZYL DISULFIDE |
Insulin |
-17% |
NoneNone |
NoneNone |
View
|
insulin receptor |
BENZOTHIAZYL DISULFIDE |
Insulin |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
FLUOCINONIDE |
Adrenergic alpha2B |
-17% |
NoneNone |
NoneNone |
View
|
synaptic vesicle glycoprotein 2b |
DIPYRIDAMOLE |
beta-Lactamase |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
CROTAMITON |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
CROTAMITON |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA1 (alpha 1) |
CORTISONE ACETATE |
Glutamate, AMPA |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2B |
TRIMETHADIONE |
Glutamate, NMDA, Phencyclidine |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
TRIMETHADIONE |
Glutamate, NMDA, Phencyclidine |
-17% |
NoneNone |
NoneNone |
View
|
N-methyl-D-aspartate receptor 1 (Grin1) gene, exons 1 through 6 and partial cds; alternatively spliced (Rn.) |
TRIMETHADIONE |
Glutamate, NMDA, Phencyclidine |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl-D-aspartate 3B |
TRIMETHADIONE |
Glutamate, NMDA, Phencyclidine |
-17% |
NoneNone |
NoneNone |
View
|
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
CINNAMALDEHYDE |
Protein Tyrosine Kinase, HER2 Receptor |
-17% |
NoneNone |
NoneNone |
View
|
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
CINNAMALDEHYDE |
Protein Tyrosine Kinase, HER2 Receptor |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
TROVAFLOXACIN |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, beta 1 |
BROMFENAC |
Adrenergic beta1 |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic, beta-1-, receptor |
BROMFENAC |
Adrenergic beta1 |
-17% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 14 |
TROVAFLOXACIN |
Protein Serine/Threonine Kinase, p38alpha |
-17% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
TROVAFLOXACIN |
Protein Serine/Threonine Kinase, p38alpha |
-17% |
NoneNone |
NoneNone |
View
|
platelet derived growth factor receptor, alpha polypeptide |
TERBUTALINE |
Platelet-Derived Growth Factor (PDGF) |
-17% |
NoneNone |
NoneNone |
View
|
platelet-derived growth factor receptor, alpha polypeptide |
TERBUTALINE |
Platelet-Derived Growth Factor (PDGF) |
-17% |
NoneNone |
NoneNone |
View
|
platelet derived growth factor receptor, beta polypeptide |
TERBUTALINE |
Platelet-Derived Growth Factor (PDGF) |
-17% |
NoneNone |
NoneNone |
View
|
platelet-derived growth factor receptor, beta polypeptide |
TERBUTALINE |
Platelet-Derived Growth Factor (PDGF) |
-17% |
NoneNone |
NoneNone |
View
|
cholinergic receptor, muscarinic 1 |
DIGITOXIN |
Muscarinic M1 |
-17% |
NoneNone |
NoneNone |
View
|
progesterone receptor |
NETILMICIN |
Progesterone |
-17% |
NoneNone |
NoneNone |
View
|
progesterone receptor |
NETILMICIN |
Progesterone |
-17% |
NoneNone |
NoneNone |
View
|
angiotensin 1 converting enzyme 1 |
TAMOXIFEN |
Protease, Angiotensin Converting Enzyme |
-17% |
NoneNone |
NoneNone |
View
|
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
TAMOXIFEN |
Protease, Angiotensin Converting Enzyme |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, NMDA2C |
TORSEMIDE |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2B |
TORSEMIDE |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
TORSEMIDE |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
N-methyl-D-aspartate receptor 1 (Grin1) gene, exons 1 through 6 and partial cds; alternatively spliced (Rn.) |
TORSEMIDE |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, N-methyl-D-aspartate 3B |
TORSEMIDE |
Glutamate, NMDA, Agonism |
-17% |
NoneNone |
NoneNone |
View
|
chemokine (C-C motif) receptor 5 |
6-METHOXY-2-NAPHTHYLACETIC ACID |
Chemokine CCR5 |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
STANOLONE |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
STANOLONE |
Cyclooxygenase COX-1 |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 1a |
ZOPICLONE |
Adrenergic alpha1A |
-17% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 5B |
MOCLOBEMIDE |
Serotonin 5-HT4 |
-17% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 4 |
MOCLOBEMIDE |
Serotonin 5-HT4 |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
SECOBARBITAL |
Calcium Channel Type L, Benzothiazepine |
-17% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 1d (Non-specific probe) |
SULFISOXAZOLE |
Adrenergic alpha1D |
-17% |
NoneNone |
NoneNone |
View
|
opioid receptor, delta 1 |
SULFISOXAZOLE |
Opiate delta |
-17% |
NoneNone |
NoneNone |
View
|
A3 adenosine receptor |
TACRINE |
Adenosine A3 |
-17% |
NoneNone |
NoneNone |
View
|